Complix N.V. believes the protein scaffolds created with its Alphabody technology will have greater stability and diversity than therapeutics based on other protein scaffolds. The resulting therapeutics could bind their targets with greater affinity than other types of proteins, and the company expects Alphabodies to be amenable to routes of administration other than injection.

The company was founded in 2008 based on the work of CSO Ignace Lasters and CEO Mark Vaeck. This is Vaeck's third venture in the next-generation protein space. He was previously CEO of Ablynx N.V., which is developing Nanobody therapeutics, and of ActoGeniX N.V., which is using genetically modified bacteria for oral delivery of protein and peptide therapeutics.